These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
197 related articles for article (PubMed ID: 17587207)
1. Prostate cancer laterality as a rationale of focal ablative therapy for the treatment of clinically localized prostate cancer. Mouraviev V; Mayes JM; Sun L; Madden JF; Moul JW; Polascik TJ Cancer; 2007 Aug; 110(4):906-10. PubMed ID: 17587207 [TBL] [Abstract][Full Text] [Related]
2. Pathologic stage T2a and T2b prostate cancer in the recent prostate-specific antigen era: implications for unilateral ablative therapy. Polascik TJ; Mayes JM; Sun L; Madden JF; Moul JW; Mouraviev V Prostate; 2008 Sep; 68(13):1380-6. PubMed ID: 18543281 [TBL] [Abstract][Full Text] [Related]
3. Appropriate candidates for hemiablative focal therapy are infrequently encountered among men selected for radical prostatectomy in contemporary cohort. Tareen B; Sankin A; Godoy G; Temkin S; Lepor H; Taneja SS Urology; 2009 Feb; 73(2):351-4; discussion 354-5. PubMed ID: 19038430 [TBL] [Abstract][Full Text] [Related]
4. Can contemporary transrectal prostate biopsy accurately select candidates for hemi-ablative focal therapy of prostate cancer? Tareen B; Godoy G; Sankin A; Temkin S; Lepor H; Taneja SS BJU Int; 2009 Jul; 104(2):195-9. PubMed ID: 19191784 [TBL] [Abstract][Full Text] [Related]
5. Predicting unilateral prostate cancer based on biopsy features: implications for focal ablative therapy--results from the SEARCH database. Scales CD; Presti JC; Kane CJ; Terris MK; Aronson WJ; Amling CL; Freedland SJ; J Urol; 2007 Oct; 178(4 Pt 1):1249-52. PubMed ID: 17698131 [TBL] [Abstract][Full Text] [Related]
6. Prostate cancer laterality does not predict prostate-specific antigen recurrence after radical prostatectomy. Mouraviev V; Sun L; Madden JF; Mayes JM; Moul JW; Polascik TJ Urology; 2007 Dec; 70(6):1141-5. PubMed ID: 18158035 [TBL] [Abstract][Full Text] [Related]
7. Discrepancy in prostate cancer localization between biopsy and prostatectomy specimens in patients with unilateral positive biopsy: implications for focal therapy. Sinnott M; Falzarano SM; Hernandez AV; Jones JS; Klein EA; Zhou M; Magi-Galluzzi C Prostate; 2012 Aug; 72(11):1179-86. PubMed ID: 22161896 [TBL] [Abstract][Full Text] [Related]
8. Side-specific factors associated with extracapsular extension and seminal vesicular invasion in men undergoing open radical retropubic prostatectomy. Sankin A; Tareen B; Lepor H Prostate Cancer Prostatic Dis; 2009; 12(2):204-8. PubMed ID: 19238170 [TBL] [Abstract][Full Text] [Related]
9. Patient selection for hemiablative focal therapy of prostate cancer: variables predictive of tumor unilaterality based upon radical prostatectomy. Polascik TJ; Mayes JM; Schroeck FR; Sun L; Madden JF; Moul JW; Mouraviev V Cancer; 2009 May; 115(10):2104-10. PubMed ID: 19288576 [TBL] [Abstract][Full Text] [Related]
10. Prostate-specific antigen improves the ability of clinical stage and biopsy Gleason sum to predict the pathologic stage at radical prostatectomy in the new millennium. Chun FK; Briganti A; Gallina A; Hutterer GC; Shariat SF; Antebie E; Walz J; Roehrborn CG; Salonia A; Rigatti P; Saad F; Huland H; Montorsi F; Graefen M; Karakiewicz PI Eur Urol; 2007 Oct; 52(4):1067-74. PubMed ID: 17383807 [TBL] [Abstract][Full Text] [Related]
12. Preoperative PSA is still predictive of cancer volume and grade in late PSA era. Figler BD; Reuther AM; Dhar N; Levin H; Magi-Galluzzi C; Zhou M; Klein EA Urology; 2007 Oct; 70(4):711-6. PubMed ID: 17991542 [TBL] [Abstract][Full Text] [Related]
13. Prostate biopsy clinical and pathological variables that predict significant grading changes in patients with intermediate and high grade prostate cancer. Moussa AS; Li J; Soriano M; Klein EA; Dong F; Jones JS BJU Int; 2009 Jan; 103(1):43-8. PubMed ID: 18782303 [TBL] [Abstract][Full Text] [Related]
15. The role of transrectal saturation biopsy in tumour localization: pathological correlation after retropubic radical prostatectomy and implication for focal ablative therapy. Abdollah F; Scattoni V; Raber M; Roscigno M; Briganti A; Suardi N; Gallina A; Capitanio U; Freschi M; Salonia A; Cestari A; Guazzoni G; Rigatti P; Montorsi F BJU Int; 2011 Aug; 108(3):366-71. PubMed ID: 21087451 [TBL] [Abstract][Full Text] [Related]
16. Laterality alone should not drive selection of candidates for hemi-ablative focal therapy. Tareen B; Godoy G; Sankin A; Temkin S; Lepor H; Taneja SS J Urol; 2009 Mar; 181(3):1082-9; discussion 1089-90. PubMed ID: 19150090 [TBL] [Abstract][Full Text] [Related]
17. Cancer ablation with regional templates applied to prostatectomy specimens from men who were eligible for focal therapy. Ward JF; Nakanishi H; Pisters L; Babaian RJ; Troncoso P BJU Int; 2009 Aug; 104(4):490-7. PubMed ID: 19220260 [TBL] [Abstract][Full Text] [Related]
18. Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities. Eggener SE; Scardino PT; Carroll PR; Zelefsky MJ; Sartor O; Hricak H; Wheeler TM; Fine SW; Trachtenberg J; Rubin MA; Ohori M; Kuroiwa K; Rossignol M; Abenhaim L; J Urol; 2007 Dec; 178(6):2260-7. PubMed ID: 17936815 [TBL] [Abstract][Full Text] [Related]
19. Prediction of extraprostatic extension by prostate specific antigen velocity, endorectal MRI, and biopsy Gleason score in clinically localized prostate cancer. Nishimoto K; Nakashima J; Hashiguchi A; Kikuchi E; Miyajima A; Nakagawa K; Ohigashi T; Oya M; Murai M Int J Urol; 2008 Jun; 15(6):520-3. PubMed ID: 18422574 [TBL] [Abstract][Full Text] [Related]
20. The maximum tumour length in biopsy cores as a predictor of outcome after radical prostatectomy. Hayashi N; Urashima M; Kuruma H; Arai Y; Kuwao S; Iwamura M; Egawa S BJU Int; 2008 Jan; 101(2):175-80. PubMed ID: 17850362 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]